Pharvaris
Vinay Edwin, MPH has a diverse work history in the field of clinical quality. Vinay currently holds the position of Director, Clinical Quality at Pharvaris, starting in November 2022. Prior to this, they worked as the Director, Clinical Quality at Karuna Therapeutics from July 2021 to November 2022. Vinay also served as the Director, Clinical Quality at Zogenix, Inc. from November 2020 to May 2021, and as the Associate Director, Clinical Quality from January 2019 to November 2020. Before their roles in the pharmaceutical industry, Vinay worked as a Consultant II - Clinical Quality at Halloran Consulting Group, Inc. from March 2016 to December 2018. Vinay also gained experience in quality assurance and compliance as a Senior Auditor at Covance from May 2015 to March 2016, and as a Clinical Quality Assurance Auditor at CSL Behring from October 2013 to May 2015. Vinay's earlier positions include serving as a Clinical Trials Auditor & Regulatory Affairs Manager at the University of Chicago Comprehensive Cancer Center from February 2012 to October 2013, as well as a Scientific Coordinator at the University of Chicago from September 2009 to September 2011. Vinay began their career as an Analytical Chemist at Regis Technologies from August 2007 to May 2008, and subsequently worked as a Business Development Specialist at the same company from June 2008 to September 2009. Vinay's first industry role was as an Analytical Chemist at Hospira, Inc. from June 2006 to August 2007.
Vinay Edwin, MPH holds a diverse education history. In 2000, they obtained their Bachelor of Science in Biology from The Ohio State University. Vinay then pursued a Master's Degree in Public Health from DePaul University, completing it in 2008. During this time, from 2009 to 2011, they also attended the University of Chicago and obtained a Graduate Certificate in Clinical Trials Management and Regulatory Compliance. In 2018, Vinay Edwin obtained the Registered Quality Assurance Professional - Good Clinical Practices certification from the Society of Quality Assurance.
This person is not in the org chart
This person is not in any offices
Pharvaris
2 followers
Pharvaris is a preclinical stage company focused on bringing an oral bradykinin B2 receptor antagonist to patients for use as an alternative to injected therapies for hereditary angioedema (HAE) and other B2 receptor-mediated indications. The company reunites the core team responsible for the discovery and approval of the HAE treatment icatibant. With novel small molecules, we have identified and are advancing potent, orally available compounds targeting this clinically proven therapeutic target.